Raffles Family Office (RFO) Thursday said it bought a stake in a privately held Hong Kong biotechnology company that works in the field of the early detection and management of cancer. The investment, part of the Cellomics’ series B funding round, was led by RFO, and follows earlier rounds backed by strategic investors, including Hong Kong-listed Jacobson Pharma and Shenzhen-listed…
To access this content, please click back to the home screen, then click “Menu” (bars in top left bars) and then “Login”.
To enquire for a free trial, please start here.
Need more help? Click here or email [email protected].
To enquire for a free trial, please start here.
Need more help? Click here or email [email protected].
Subscriber Only Content
This article is available on a corporate subscription with Asian Private Banker. Please login or subscribe to view this content.
Need help? Please see our FAQ Guide or email [email protected]